



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 98,385-H)

In the Application of:

Hauptmann et al.

Serial No.: 09/899,422

Filing Date: July 3, 2001

For: TNF receptors, TNF binding proteins
and DNAs coding for them

Examiner: E. O'Hara

Group Art Unit: 1646

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to resubmit the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.


Date: March 17, 2004

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

A handwritten signature in black ink, appearing to read "Donald L. Zuhn", written over a horizontal line.

Donald L. Zuhn

Reg. No. 48,710

SUBSTITUTE for form 149/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	09/899,422
				Filing Date:	7-3-01
				First Named Inventor	Hauptmann
				Group Art Unit	1646
Examiner Name	E. O'Hara				
Attorney Docket No.	98-385-H				
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		DE	3913101.7	A1	Boehringer Ingelheim International GmbH			

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HELLER <i>et al.</i> , "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor," <i>Proc. Natl. Acad. Sci.</i> 87: 6151-55 (1990).	
		PEPPEL <i>et al.</i> , "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> 174:1483-89 (1991).	
		TSUJIMOTO <i>et al.</i> , "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells," <i>Archives of Biochemistry</i> 249(2):563-568(1986).	
		POWELL <i>et al.</i> , "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS," <i>Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine.</i> pgs 355-69.	
		RHEIN <i>et al.</i> , "Another Sepsis Drug Down-Immunex TNF Receptor," <i>Biotechnology Newswatch</i> , pg. 1,3 (Monday, October 4, 1991).	
		VILCEK <i>et al.</i> , "Tumor Necrosis Factor: Receptor Binding and Mitogenic Action in Fibroblasts," <i>J. Cell. Physiol.</i> 5:57-61 (1987).	
		SMITH <i>et al.</i> , "Species Specificity of Human and Murine Tumor Necrosis Factor," <i>The Journal of Biological Chemistry</i> , 251(32):14871-148874 (1986).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231